



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/470,494	12/22/1999	MARTHA K. NEWELL	10277/7007	6216
75	90 09/23/2003			
WOLF GREENFIELD & SACKS P C			EXAMINER	
600 ATLANTIC AVENUE BOSTON, MA 02210			GAMBEL, PHILLIP	
	•		ART UNIT	PAPER NUMBER
			1644	10
			DATE MAILED: 09/23/2003	19

Please find below and/or attached an Office communication concerning this application or proceeding.

1.	Application No.	Applicant(s)				
Office Action Summary	Examiner CAMBEL	Nemar				
omos Acabin Summary	Examiner	Art Unit				
	Cambic	1644				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	errespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE						
Status						
1) Responsive to communication(s) filed on 6(9(0)) 2a) This action is FINAL. 2b) This action is non final.						
This doubt is not-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
4) Claim(s) is/are pending in the application. 1 - 103						
4a) Of the above claim(s) is/are withdrawn from consideration. 41+6667-103						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement. / - 40, 47 % Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on injected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action:						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No.						
Opties of the certified copies of the priority documents have been a						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic p	priority under 35 U.S.C. 8 119(a)	(to a provintend and in the continue)				
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)	710/1ty under 35 U.S.C. §§ 120 a	nd/or 121.				
1) Notice of References Cited (PTO-892)	4) Interview Summary (P					
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pate 6) Other:	TO-413) Paper No(s) ent Application (PTO-152)				
J.S. Patent and Trademark Office						
PTO-326 (Rev. 04-01) Office Action	1 Summary	Part of Paper No. /G				

Moor No 19

DETAILED ACTION

- 1. Applicant's election of CD86 as the co-stimulatory agent in Paper No. 18, filed 6/9/03 and applicant's election of the CD40 ligand as the CD40 binding agent in Paper No. 13, file 8/6/01 with respect to Group I (claims 1-40 and 47-66) are acknowledged.
- 2. Upon a review of the instant application, the following species election is set forth. The examiner apologizes for any inconvenience to applicant in this matter.

This application contains claims directed to the following patentably distinct species of the elected Group I: wherein the method is:

- A) in vivo (e.g. the CD40 ligand and CD86 are administered in vivo in a subject) or
- B) in vitro / ex vivo (e.g. the T cells are treated in vitro / ex vivo with CD40 ligand and CD86).

These species are distinct because the ingredients, methods steps and endpoints differ

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1 and 41 are generic for example.

3. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Serial No. 09/470494 Art Unit 1644

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 6. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Applicant is invited to review the instant specification. For example, see page 11, lines 19-20 of the instant specification.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 872-9306.

Phillip Gambel, PhD. Primary Examiner Technology Center 1600

PHULL GAMBUS

September 22, 2003